Andrew F. Nolting
Research Subjects
Andrew F. Nolting has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Erik L. Regalado
Analytical Research and Development, MRL, Merck & Co., Inc., Rahway, NJ 07065, USA
2 shared publications - Mirlinda Biba
Merck & Co., Inc., Rahway, New Jersey 07065, United States
2 shared publications - Qi Gao
Analytical Research & Development, Merck & Co., Inc , Rahway , NJ 07065
2 shared publications - Alexei V. Buevich
†Department of Discovery Chemistry; ‡Department of Quantitative Biosciences; §Department of Discovery Oncology; ∥Department of Pharmacokinetics; ⊥Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., Rahway, New Jersey 07065, United States
1 shared publication - Alexey A. Makarov
Discovery Analytical Research, MRL, Merck & Co., Inc
1 shared publication Anagha Chandra
Department of Process Research and Development
1 shared publication
Latest Publications
- Top Cited Papers
- 24 March 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (13) , 11036-11048
Total Synthesis of Enlicitide Decanoate
We report the total synthesis of enlicitide decanoate, an orally bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 that is being developed for the treatment of atherosclerotic cardiovascular disease. It is a highly complex macrocyclic peptide with a significant number of nonpeptide structural elements that presents a daunting synthetic chemistry challenge. We describe the development of a convergent, efficient, and robust manufacturing process that enables the large-scale production of enlicitide.
- 24 March 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (13) , 11036-11048
Top Cited PapersTotal Synthesis of Enlicitide Decanoate
We report the total synthesis of enlicitide decanoate, an orally bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 that is being developed for the treatment of atherosclerotic cardiovascular disease. It is a highly complex macrocyclic peptide with a significant number of nonpeptide structural elements that presents a daunting synthetic chemistry challenge. We describe the development of a convergent, efficient, and robust manufacturing process that enables the large-scale production of enlicitide.
- 7 September 2023
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 88 (19) , 13454-13465
Diastereoselective Reductive Etherification Via High-Throughput Experimentation: Access to Pharmaceutically Relevant Alkyl Ethers
This manuscript describes the development of the first diastereoselective intermolecular synthesis of alkyl ethers via reductive etherification of diverse ketones or aldehydes with alcohols. Key to this development was the use of low-temperature high-throughput experimentation (HTE) technologies that enabled rapid reaction optimizations and parallel synthesis. A broad scope of pharmaceutically relevant substrates was surveyed, which formed alkyl ethers effectively. In addition, we demonstrated that the diastereoselectivity of this transformation can be readily modulated by prudent selection of the reductant.
- 7 September 2023
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 88 (19) , 13454-13465
Diastereoselective Reductive Etherification Via High-Throughput Experimentation: Access to Pharmaceutically Relevant Alkyl Ethers
This manuscript describes the development of the first diastereoselective intermolecular synthesis of alkyl ethers via reductive etherification of diverse ketones or aldehydes with alcohols. Key to this development was the use of low-temperature high-throughput experimentation (HTE) technologies that enabled rapid reaction optimizations and parallel synthesis. A broad scope of pharmaceutically relevant substrates was surveyed, which formed alkyl ethers effectively. In addition, we demonstrated that the diastereoselectivity of this transformation can be readily modulated by prudent selection of the reductant.
- 11 May 2022
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 24 (19) , 3455-3460
Asymmetric Synthesis of Tertiary and Secondary Cyclopropyl Boronates via Cyclopropanation of Enantioenriched Alkenyl Boronic Esters
The cyclopropanation of alkenyl boronates and subsequent derivatization of the boronate handle are a convenient strategy to quickly build molecular complexity and access diverse compounds with a high sp3 fraction. Herein, we describe the asymmetric cyclopropanation of enantioenriched hydrobenzoin-derived alkenyl boronic esters toward the synthesis of tertiary and secondary cyclopropyl boronates.
- 11 May 2022
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 24 (19) , 3455-3460
Asymmetric Synthesis of Tertiary and Secondary Cyclopropyl Boronates via Cyclopropanation of Enantioenriched Alkenyl Boronic Esters
The cyclopropanation of alkenyl boronates and subsequent derivatization of the boronate handle are a convenient strategy to quickly build molecular complexity and access diverse compounds with a high sp3 fraction. Herein, we describe the asymmetric cyclopropanation of enantioenriched hydrobenzoin-derived alkenyl boronic esters toward the synthesis of tertiary and secondary cyclopropyl boronates.
- 21 December 2021
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (1) , 485-496
Development of ProTx-II Analogues as Highly Selective Peptide Blockers of Nav1.7 for the Treatment of Pain
Inhibitor cystine knot peptides, derived from venom, have evolved to block ion channel function but are often toxic when dosed at pharmacologically relevant levels in vivo. The article describes the design of analogues of ProTx-II that safely display systemic in vivo blocking of Nav1.7, resulting in a latency of response to thermal stimuli in rodents. The new designs achieve a better in vivo profile by improving ion channel selectivity and limiting the ability of the peptides to cause mast cell degranulation. The design rationale, structural modeling, in vitro profiles, and rat tail flick outcomes are disclosed and discussed.
- 21 December 2021
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (1) , 485-496
Development of ProTx-II Analogues as Highly Selective Peptide Blockers of Nav1.7 for the Treatment of Pain
Inhibitor cystine knot peptides, derived from venom, have evolved to block ion channel function but are often toxic when dosed at pharmacologically relevant levels in vivo. The article describes the design of analogues of ProTx-II that safely display systemic in vivo blocking of Nav1.7, resulting in a latency of response to thermal stimuli in rodents. The new designs achieve a better in vivo profile by improving ion channel selectivity and limiting the ability of the peptides to cause mast cell degranulation. The design rationale, structural modeling, in vitro profiles, and rat tail flick outcomes are disclosed and discussed.